^
H3.3K27M
Glioma
anlotinib
Sensitive: C4 – Case Studies
Acta Neurochir (Wien) - 1 week
IDH2 mutation
GBM
AV-GBM-1
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
IDH1 mutation
GBM
AV-GBM-1
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
MGMT promoter methylation
GBM
AV-GBM-1
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
No biomarker
GBM
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Brain Cancer
lomustine
Sensitive: A1 - Approval
No biomarker
Astrocytoma
everolimus
Sensitive: A1 - Approval
No biomarker
Astrocytoma
carmustine
Sensitive: A1 - Approval
No biomarker
Ependymoma
carmustine
Sensitive: A1 - Approval
No biomarker
Medulloblastoma
carmustine
Sensitive: A1 - Approval
No biomarker
Anaplastic Astrocytoma
temozolomide
Sensitive: A1 - Approval
No biomarker
GBM
bevacizumab
Sensitive: A1 - Approval
No biomarker
Glioma
carmustine
Sensitive: A1 - Approval
No biomarker
GBM
temozolomide
Sensitive: A1 - Approval
No biomarker
GBM
carmustine
Sensitive: A1 - Approval
No biomarker
GBM
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
GBM
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
GBM
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Glioma
teserpaturev
Sensitive: A1 - Approval
BRAF V600E
GBM
trametinib + dabrafenib
Sensitive: A2 - Guideline
No biomarker
GBM
PCV
Sensitive: A2 - Guideline
No biomarker
Anaplastic Astrocytoma
PCV
Sensitive: A2 - Guideline
No biomarker
Glioma
PCV
Sensitive: A2 - Guideline
MGMT promoter methylation
GBM
temozolomide
Sensitive: A2 - Guideline
No biomarker
Oligodendroglioma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Glioma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Meningioma
bevacizumab + everolimus
Sensitive: A2 - Guideline
No biomarker
Meningioma
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Meningioma
sunitinib
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cisplatin + cyclophosphamide oral + vincristine
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cisplatin + vincristine + lomustine
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
trametinib + dabrafenib
Sensitive: A2 - Guideline
No biomarker
Glioma
bevacizumab
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
No biomarker
Astrocytoma
lomustine + procarbazine hydrochloride + vincristine liposomal
Sensitive: A2 - Guideline
No biomarker
GBM
lomustine
Sensitive: A2 - Guideline
No biomarker
GBM
regorafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
No biomarker
Astrocytoma
temozolomide gel
Sensitive: A2 - Guideline
BRAF V600E
Glioma
selumetinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
trametinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
trametinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
dabrafenib
Sensitive: A2 - Guideline
NTRK3 fusion
Glioma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Glioma
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Glioma
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Glioma
lomustine
Sensitive: A2 - Guideline
NTRK3 fusion
Glioma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Glioma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Glioma
entrectinib
Sensitive: A2 - Guideline
BRAF V600E
GBM
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF fusion
Glioma
selumetinib
Sensitive: A2 - Guideline
NTRK3 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
No biomarker
Ependymoma
lomustine
Sensitive: A2 - Guideline
No biomarker
Ependymoma
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Glioma
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Ependymoma
lapatinib
Sensitive: A2 - Guideline
No biomarker
Ependymoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Ependymoma
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Meningioma
DG3173
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
vismodegib
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cisplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
etoposide oral
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cyclophosphamide oral + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
carboplatin + cyclophosphamide oral + etoposide oral
Sensitive: A2 - Guideline
No biomarker
GBM
VAL-083
Sensitive: B - Late Trials
No biomarker
GBM
enzastaurin
Sensitive: B - Late Trials
No biomarker
GBM
DNX-2401
Sensitive: B - Late Trials
H3.3K27M
Glioma
ONC201
Sensitive: B - Late Trials
No biomarker
GBM
GDC-0084
Sensitive: B - Late Trials
MGMT unmethylation
GBM
temozolomide
Sensitive: B - Late Trials
IDH1 mutation
Glioma
temozolomide gel
Sensitive: B - Late Trials
IDH1 R132H
Anaplastic Astrocytoma
temozolomide
Sensitive: B - Late Trials
IDH2 mutation
Glioma
temozolomide
Sensitive: B - Late Trials
IDH1 mutation
Glioma
temozolomide
Sensitive: B - Late Trials
MGMT promoter methylation
Anaplastic Astrocytoma
temozolomide
Sensitive: B - Late Trials
IDH2 mutation
Glioma
temozolomide gel
Sensitive: B - Late Trials
IDH1 mutation
Glioma
PCV
Sensitive: B - Late Trials
IDH2 mutation
Glioma
PCV
Sensitive: B - Late Trials
No biomarker
GBM
GLR2007
Sensitive: B - Late Trials
No biomarker
GBM
VB-111
Sensitive: B - Late Trials
No biomarker
Glioma
OKN-007
Sensitive: B - Late Trials
No biomarker
GBM
CYNK-001
Sensitive: B - Late Trials